Stock Ratings / Health Care / PMVP / options

VTVT (33) PMN (40) ORGO (50) MIST (47) ⌘ Pro Terminal →

PMV Pharmaceuticals Inc. (PMVP) Options Positioning, Max Pain & Unusual Sweeps

$1.31 -2.96% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.30

PMV Pharmaceuticals Inc. (PMVP) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $101.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PMVP Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PMVP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, PMV Pharmaceuticals Inc. (NASDAQ: PMVP) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $1.31 (-2.96% 1D, market cap $101.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PMVP ranks #415 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PMVP compare to VTVT and PMN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PMVP carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VTVT (vTv Therapeutics Inc. (Class A)) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $104.3M) and PMN (ProMIS Neurosciences Inc. (ON)) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $99.4M). Among the 5-stock peer group, PMVP leads on earnings multiple (N/A) while ORGO leads on capital efficiency (17.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PMVP?

▼

Per PMVP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001699382), PMV Pharmaceuticals Inc. generated $0 in revenue, -$77.7M in net income, and -$73.6M in free cash flow against $116.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.30 (-0.72%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-6.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PMVP)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (45/100 Composite)

🔍 WHY PMVP SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (33% of score)

FRED Regime × Technicals: 33% of 52W Range • RSI-14 at 50.6 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$1.41-11.3% Next Q

Q2 (-2Q)

Grade C-$1.25-9.6% Next Q

Q3 (-1Q)

Grade D$1.13+15.9% Next Q

Current

Grade D$1.31-6.3% Hist 90D α

Trajectory: C- (53) → D (45)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PMVP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PMVP currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.38) and Max Pain ($1.38) forces dealer call-delta covering toward $2.01.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PMVP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PMVP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 45%NO 55%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (PMVP)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for PMVP.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PMVP)

✓Walkthrough of PMVP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PMVP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -6.43%▲ ASCENDING CHANNEL

2026-11-02O $1.33H $1.39L $1.31C $1.31VOL 298.6K

RES: $2.09SUP: $1.11SMA50: $1.38SMA200: $1.30

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PMVP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PMVP Butterfly Map → + Track PMVP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PMVP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PMVP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PMVP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PMVP)

Health Care Rank #415 of 1016 ⚔️ VTVT vs PMVP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PMVP vs. VTVT, PMN, ORGO, MIST)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, PMV Pharmaceuticals Inc. (PMVP) ranks #415 by composite RQD confidence (45/100, grade D) and #660 by equity capitalization ($101.9M). Within this direct 5-issuer industry benchmark cohort, PMVP leads on earnings valuation at N/A trailing P/E, while ORGO leads on capital efficiency and profitability with 17.1% ROIC and — gross margin. ORGO currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with PMVP at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PMVP ACTIVE PMV Pharmaceuticals Inc.	D	45/100	—	—	-35.0%	-2.96%	$101.9M	Benchmark Subject
VTVT vTv Therapeutics Inc. (Class A)	E	33/100	—	—	-35.0%	-4.59%	$104.3M	/vtvt-vs-pmvp →
PMN ProMIS Neurosciences Inc. (ON)	D-	40/100	—	—	-35.0%	-70.13%	$99.4M	/pmn-vs-pmvp →
ORGO Organogenesis Holdings Inc. (Class A)	D	50/100	—	—	17.1%	-6.20%	$105.4M	/orgo-vs-pmvp →
MIST Milestone Pharmaceuticals Inc.	D	47/100	—	—	-35.0%	-7.55%	$98.3M	/mist-vs-pmvp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001699382

In its most recent audited fiscal period (FY2025, filed 2025-12-31), PMV Pharmaceuticals Inc. (PMVP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$77.7M, operating cash flow of -$73.6M, and free cash flow of -$73.6M (-41.7% YoY). On the balance sheet, PMVP closed FY2025 with $116.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$77.7M	-$73.6M	-$73.6M	$116.6M	—
FY2024 (FY)	2024-12-31	$0	-$58.9M	-$51.3M	-$51.9M	$191.3M	—
FY2023 (FY)	2023-12-31	$0	-$69.0M	-$55.7M	-$55.7M	—	—

3. PMVP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PMVP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PMVP compare to VTVT and PMN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PMVP?

Where is PMVP trading relative to its 50-day, 200-day, and 52-week technical levels?

PMVP last traded at $1.31 (-2.96% on volume of 1,212,928 shares), positioning the stock -5.07% below its 50-day simple moving average ($1.38) and +0.77% above its 200-day simple moving average ($1.30). Across its 52-week range of $1.02 to $1.91, PMVP sits at the 32.6% percentile with a 14-day RSI of 50.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.15 to $1.47).

PMVP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is PMVP's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for PMVP.

Direct Sub-Reports: PMVP RQD Cockpit PMVP 12M Forecast PMVP Earnings & Move PMVP Dividends & DRIP PMVP Insiders & 13F PMVP Whale Options PMVP Profit Sankey PMVP News & Why

ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PMVP — PMV Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:44:04Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PMVP scores 45/100 for a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." Across the five pillars: the Fundamental Cash Engine scores 6/20 (ROIC of -35%; FCF yield of 0%), indicating the business is not currently generating returns on invested capital or free cash flow. Whale/13F Flow scores 9/20 (institutional accumulation and options positioning), a weak signal of smart-money conviction. Insider Conviction scores 5/20 (SEC Form 4 and Congressional PTR cluster flow), indicating limited insider or congressional confidence. Macro Regime Fit scores 15/20 (Beta 1.0; sector sensitivity), meaning the stock's market sensitivity is neutral, not a differentiator. Forensic Balance Sheet scores 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5), a middling-to-weak reading on financial health. For a prospective investor, the upside case depends on a turnaround in cash generation that the reported metrics do not yet show, while the valuation tradeoff is that the company has no earnings-based multiple to anchor value. The negative ROIC and zero FCF yield mean the equity case rests on factors outside current operating performance.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-86.2M	$-77.7M	N/A	$-73.6M	$38.0M	N/A
FY 2024	$0.0M	$-85.4M	$-58.9M	N/A	$-51.9M	$40.9M	N/A
FY 2023	$0.0M	$-80.1M	$-69.0M	N/A	$-55.7M	N/A	N/A

Per the SEC financials, revenue is $0.0M across all three periods, and operating income, net income, and free cash flow are negative in each. Gross, operating, and net margins are each 0% per the market data, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, per the Roarable RQD rating's forensic pillar, with Debt/Equity of 0.5. Cash declined from $40.9M (FY 2024) to $38.0M (FY 2025).

Recent Catalysts & News Wire Analysis

Per the recent news feed, six items are tagged to PMVP, all marked YELLOW with impact label MARKET WIRE: a Yahoo Finance report on a 19% three-month share rise; a Seeking Alpha piece framing mutant P53 restoration as a potential mispriced cancer opportunity; a kalkine.ca share-price update; a TradingView estimates page; an Investing.com item reporting that Matt Eckler was appointed to the board of directors; and an ad-hoc-news.de item reporting the stock moved above its 200-day average while analysts remain mixed. Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals. Risk watch items drawn from the financials include continued operating losses and negative free cash flow across all reported periods.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no upstream or downstream dependencies, no butterfly links, and no proprietary signals recorded. Sector correlation data is not available in source data. The 2nd-order bottleneck a prospective investor should monitor is therefore not identifiable from the supplied sources; the company's own cash balance trajectory ($40.9M to $38.0M) against sustained negative free cash flow is the only documented pressure point.

Analyst View & Smart Money Ownership

Analyst data is not available in source data. Holder data is not available in source data. No consensus rating, price targets, SEC Form 4 insider trades, 13F institutional holdings, or Congressional trades are provided. The Roarable RQD insider and whale pillars score 5/20 and 9/20 respectively, which reflects the rating's assessment of flow, but the underlying trade-level data is not included.

Open Questions

What are PMVP's products, clinical programs, and revenue model, given that reported revenue is $0.0M in every period?
What is the company's debt position in dollar terms, since debt is listed as N/A despite a Debt/Equity ratio of 0.5?
What is the cash runway implied by $38.0M in cash against FY 2025 free cash flow of $-73.6M?
What are the trade-level details behind the 13F, Form 4, and Congressional flow signals that drive the 9/20 and 5/20 pillar scores?
What clinical, regulatory, or financing catalysts are scheduled, and what is the source of the mutant P53 thesis referenced in the news feed?

PMVP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for PMV Pharmaceuticals Inc. (PMVP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PMVP Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 5h ago

PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know

Yahoo Finance report covering PMV Pharmaceuticals Inc. (PMVP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 8h ago

PMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer Opportunity

Seeking Alpha report covering PMV Pharmaceuticals Inc. (PMVP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE kalkine.ca • 11h ago

Pmv Pharmaceuticals Inc (NASDAQ: PMVP) Share Price, PMVP Stock News, PMVP Share Price & Updates

kalkine.ca report covering PMV Pharmaceuticals Inc. (PMVP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 14h ago

PMV Pharmaceuticals, Inc. Estimates – NASDAQ:PMVP

TradingView report covering PMV Pharmaceuticals Inc. (PMVP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com India • 17h ago

PMV Pharma appoints Matt Eckler to board of directors By Investing.com

Investing.com India report covering PMV Pharmaceuticals Inc. (PMVP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 20h ago

PMV Pharmaceuticals stock moves above 200-day average as analysts stay mixed

ad-hoc-news.de report covering PMV Pharmaceuticals Inc. (PMVP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 23h ago

Should You Buy PTC Inc. (PTC) After Golden Cross?

Yahoo Finance report covering PMV Pharmaceuticals Inc. (PMVP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

PMVP Q3'26 Earnings: revenue estimate is 0 USD

TradingView report covering PMV Pharmaceuticals Inc. (PMVP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PMVP Bull vs. Bear Conversation Board — What's Your Call at $1.31?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PMVP 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.19 (-11.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is PMVP (D • RQD 45/100) a Buy at $1.35?

Welcome to the PMVP (PMV Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 45/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.07 (-20.7%)

Spot @ $1.35

Pump the brakes on PMVP — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PMVP, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless PMV Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.67 (+23.7%)

Spot @ $1.35

PMVP cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PMVP, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.35 (52-wk range $1.17 - $1.47), any beat on forward guidance forces shorts and underweight funds to chase.